Jaguar Health, Inc. announced that it has appointed David MacNaughtan, an executive with more than 25 years of biopharmaceutical industry experience with roles spanning financing, venture capital, royalty investing, business development, and process development, to the company’s board of directors. Most recently,he led the intellectual property investing strategy at CPPIB Credit Investments Inc. for eight years, focused on the acquisition and securitization of pharmaceutical royalty streams. Prior to this, he was co-head of the royalty monetization fund at DRI Capital. From 1999 to 2002, he was Vice President of Business Development at Paladin Labs where he led a team responsible for acquiring and licensing products for the Canadian market. He joined Paladin from Royal Bank Capital Corp. where he was an investment manager. He began his career in the biopharmaceutical industry at Hemosol Inc. as a process development engineer.